At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 165 enrolled
Drug / intervention
teriparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Ranging Study of the Effects of Macroflux® PTH Compared With Macroflux® Placebo and FORTEO® in Postmenopausal Women With Osteoporosis
In Brief
A Phase 2 clinical trial evaluating teriparatide for Osteoporosis. Completed, enrolled 165 participants.
Detailed Summary
A Multi-center study to determine effects of various doses of Macroflux Parathryroid Hormone (PTH) in women with osteoporosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJun 2007
Primary CompletionApr 2008
Study CompletionAug 2008
TodayJul 2026
First PostedJun 21, 2007
Enrollment StartJun 1, 2007
Primary CompletionApr 1, 2008
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.0 years ago
Interventions
teriparatidedrug
Macroflux® patch applied to the abdomen for 30 minutes daily
teriparatidedrug
FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh